Protocol Ledger

NCT05357989 · Phase III · COMPLETED

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Interventional Phase III clinical trial protocol NCT05357989 sponsored by Annovis Bio in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-03 Enrollment: 523 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05357989
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)523 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05357989
Protocol FieldVerified Registry Value
NCT IdentifierNCT05357989
Consolidated Lead SponsorAnnovis Bio
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment523 participants (ACTUAL)
Registered Start Date2022-08-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05357989
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI